Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)

Exclusion Criteria

• •Biopsy-proven differentiated VIN;
• •Any previous treatment for vulvar HSIL within 4 weeks prior to screening;
• •Allergy to imiquimod 5% cream or to an inactive ingredient in imiquimod 5% cream;
• •Pregnant, breastfeeding or considering becoming pregnant within 6 months following the last dose of investigational product;
• •Immunosuppression as a result of underlying illness or treatment;
• •Significant acute or chronic medical illness.